Products, Major Customer, Concentration of Credit Risk (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Concentration Risk [Line Items]
Total property and equipment, cost	$ 198,773,000	$ 182,950,000
Domestic Country [Member]
Concentration Risk [Line Items]
Revenue, Net	0.75	0.74	0.76
Total property and equipment, cost	129,900,000	116,100,000
Foreign Country [Member]
Concentration Risk [Line Items]
Revenue, Net	0.25	0.26	0.24
Total property and equipment, cost	68,900,000	66,800,000
MEXICO
Concentration Risk [Line Items]
Total property and equipment, cost	47,500,000	46,400,000
SLOVAKIA
Concentration Risk [Line Items]
Total property and equipment, cost	16,200,000	15,200,000
ITALY
Concentration Risk [Line Items]
Total property and equipment, cost	5,000,000	5,000,000
GERMANY
Concentration Risk [Line Items]
Total property and equipment, cost	200,000	200,000
Hospira [Member]
Concentration Risk [Line Items]
Revenue, Net	0.42	0.42	0.44
Entity Wide Accounts Receivable Major Customer Percent	0.35	0.36
Infusion Therapy Revenue [Member]
Concentration Risk [Line Items]
Revenue, Net	215,300,000	198,900,000	188,100,000
Critical Care Revenue [Member]
Concentration Risk [Line Items]
Revenue, Net	55,500,000	61,400,000	63,600,000
Oncology Revenue [Member]
Concentration Risk [Line Items]
Revenue, Net	30,300,000	24,400,000	18,300,000
Other Revenue [Member]
Concentration Risk [Line Items]
Revenue, Net	$ 15,800,000	$ 17,500,000	$ 13,000,000